Kancera reports results from a collaboration with Professor Hakan Mellstedts research group at Karolinska Institute showing that the survival of an aggressive type of human cancer cells from pancreatic cancer is ROR-1 dependent. The results provide further support for the Kancera ROR project developing an effective drug against this severe cancer. Kancera has previously reported results showing that the expression of ROR protein in cancer cells from the pancreas is high and that Kancera's small molecule ROR inhibitors efficiently kill these cancer cells...
More...
More...